Measuring silent MS progression with advanced tests
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing-remitting or primary progressive MS (using the 2017 McDonald criteria).
- You are currently being treated with a monoclonal antibody like natalizumab, ofatumumab, or ocrelizumab.
- Your disability level is at or below 7.0 on the EDSS scale (you can walk with or without help).
- You have not had an MS relapse or received IV steroids in the past 6 weeks.
- You are not pregnant, and you are not taking any other immune-suppressing medications besides the monoclonal antibody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses MRI scans to monitor spinal cord changes in people newly diagnosed with relapsing-remitting MS who have not yet started treatment. It aims to better understand how the disease progresses and could help guide early treatment decisions.
This study measures specific proteins in your blood that may help doctors understand how progressive multiple sclerosis advances. By tracking these markers over time, researchers hope to better predict disease progression and improve treatment decisions.
This study looks at why some people with relapsing-remitting multiple sclerosis (RRMS) get worse even when they don't have relapses. It uses eye scans and other tests to find early signs of progression, which could help tailor treatments.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial is studying how multiple sclerosis (MS) progresses over time. It may help researchers understand the disease better.
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.